These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 34955003)

  • 21. Central vascular structures as a characteristic finding of regenerative nodules using hepatobiliary phase gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid-enhanced MRI and arterial dominant phase contrast-enhanced US.
    Sugimori K; Numata K; Okada M; Nihonmatsu H; Takebayashi S; Maeda S; Nakano M; Tanaka K
    J Med Ultrason (2001); 2017 Jan; 44(1):89-100. PubMed ID: 27771842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Magnetic Resonance Imaging With Extracellular Contrast Detects Hepatocellular Carcinoma With Greater Accuracy Than With Gadoxetic Acid or Computed Tomography.
    Min JH; Kim JM; Kim YK; Cha DI; Kang TW; Kim H; Choi GS; Choi SY; Ahn S
    Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2091-2100.e7. PubMed ID: 31843599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic criteria for hepatocellular carcinoma ⩽3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging.
    Choi SH; Byun JH; Lim YS; Yu E; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    J Hepatol; 2016 May; 64(5):1099-1107. PubMed ID: 26820629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosis of recurrent HCC: intraindividual comparison of gadoxetic acid MRI and extracellular contrast-enhanced MRI.
    Yim JH; Kim YK; Min JH; Lee J; Kang TW; Lee SJ
    Abdom Radiol (NY); 2019 Jul; 44(7):2366-2376. PubMed ID: 30847566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T1 mapping combined with Gd-EOB-DTPA-enhanced magnetic resonance imaging in predicting the pathologic grading of hepatocellular carcinoma.
    Chen CY; Chen J; Xia CC; Huang ZX; Song B
    J Biol Regul Homeost Agents; 2017; 31(4):1029-1036. PubMed ID: 29254310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do transition and hepatobiliary phase hypointensity improve LI-RADS categorization as an alternative washout: a systematic review and meta-analysis.
    Pan J; Tao Y; Chi X; Yang L; Zhao Y; Chen F
    Eur Radiol; 2022 Aug; 32(8):5134-5143. PubMed ID: 35267090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study.
    Granito A; Galassi M; Piscaglia F; Romanini L; Lucidi V; Renzulli M; Borghi A; Grazioli L; Golfieri R; Bolondi L
    Aliment Pharmacol Ther; 2013 Feb; 37(3):355-63. PubMed ID: 23199022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on MR Contrast Agents for Liver Imaging: What to Use and When.
    Kalor A; Girometti R; Maheshwari E; Kierans AS; Pugliesi RA; Buros C; Furlan A
    Radiol Clin North Am; 2022 Sep; 60(5):679-694. PubMed ID: 35989037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI.
    Bae JS; Lee JM; Yoon JH; Kang HJ; Jeon SK; Joo I; Lee KB; Kim H
    Radiology; 2021 May; 299(2):336-345. PubMed ID: 33650901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The usefulness of contrast-enhanced ultrasonography in the early detection of hepatocellular carcinoma viability after transarterial chemoembolization: pilot study.
    Cho YZ; Park SY; Choi EH; Baik SK; Kwon SO; Kim YJ; Cha SH; Kim MY
    Clin Mol Hepatol; 2015 Jun; 21(2):165-74. PubMed ID: 26157754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: Comparison with ultrasound.
    Park HJ; Jang HY; Kim SY; Lee SJ; Won HJ; Byun JH; Choi SH; Lee SS; An J; Lim YS
    J Hepatol; 2020 Apr; 72(4):718-724. PubMed ID: 31836549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging.
    Zech CJ; Ba-Ssalamah A; Berg T; Chandarana H; Chau GY; Grazioli L; Kim MJ; Lee JM; Merkle EM; Murakami T; Ricke J; B Sirlin C; Song B; Taouli B; Yoshimitsu K; Koh DM
    Eur Radiol; 2020 Jan; 30(1):370-382. PubMed ID: 31385048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A study on the inconsistency of arterial phase hypervascularity detection between contrast-enhanced ultrasound using sonazoid and gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid magnetic resonance imaging of hepatocellular carcinoma lesions.
    Wang F; Numata K; Chuma M; Miwa H; Moriya S; Ogushi K; Okada M; Otani M; Inayama Y; Maeda S
    J Med Ultrason (2001); 2021 Apr; 48(2):215-224. PubMed ID: 33721130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic performance of MRI for HCC according to contrast agent type: a systematic review and meta-analysis.
    Kim DW; Choi SH; Kim SY; Byun JH; Lee SS; Park SH; Kim KW
    Hepatol Int; 2020 Dec; 14(6):1009-1022. PubMed ID: 33146841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.
    Granata V; de Lutio di Castelguidone E; Fusco R; Catalano O; Piccirillo M; Palaia R; Izzo F; Gallipoli AD; Petrillo A
    Radiol Med; 2016 Feb; 121(2):122-31. PubMed ID: 26345332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules ≤2 cm in cirrhosis.
    Ayuso C; Forner A; Darnell A; Rimola J; García-Criado Á; Bianchi L; Vilana R; Oliveira R; Llarch N; Bruix J
    Liver Int; 2019 Jul; 39(7):1281-1291. PubMed ID: 31077539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Usefulness of combination of imaging modalities in the diagnosis of hepatocellular carcinoma using Sonazoid®-enhanced ultrasound, gadolinium diethylene-triamine-pentaacetic acid-enhanced magnetic resonance imaging, and contrast-enhanced computed tomography.
    Alaboudy A; Inoue T; Hatanaka K; Chung H; Hyodo T; Kumano S; Murakami T; Moustafa EF; Kudo M
    Oncology; 2011; 81 Suppl 1():66-72. PubMed ID: 22212939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
    Lee S; Kim SS; Chang DR; Kim H; Kim MJ
    Clin Mol Hepatol; 2020 Jul; 26(3):340-351. PubMed ID: 32492765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
    Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
    J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid.
    Semaan S; Vietti Violi N; Lewis S; Chatterji M; Song C; Besa C; Babb JS; Fiel MI; Schwartz M; Thung S; Sirlin CB; Taouli B
    Eur Radiol; 2020 Feb; 30(2):1020-1030. PubMed ID: 31673837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.